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BiomarkerAbnormal oscillatory activity in the basal ganglia is increasingly implicated in the pathophysiology of Parkin-
son's disease. Such activity is recorded in patients in the form of oscillations in the local ﬁeld potential (LFP)
picked up in the subthalamic nucleus. Previous studies have focused on correlations between features of the
time averaged power or amplitude spectrum of the LFP and the clinical state, either off medication or in re-
sponse to levodopa. However, average spectral densities do not take account of time variant spectral proper-
ties and we hypothesised that these dynamic properties of the spectrum of the LFP would contain additional
information about clinical state. Here we assess the variability in LFP amplitude over time using the coefﬁ-
cient of variation (CV), evaluating this with regard to clinical state off medication and in response to levodopa
in two datasets. The CV of activity in the high beta frequency band was found to be correlated with clinical
state off levodopa (rho=−0.59, pb0.001) and this was shown to be complementary, rather than redundant,
to spectral amplitude in a multiple regression analysis, selective for rigidity–bradykinesia and highly focal.
Similarly, a strong correlation was found between change in clinical scores and change in high beta CV fol-
lowing levodopa (rho=−0.66, p=0.004). This too was selective for rigidity–bradykinesia and non-
redundant to spectral power in a multiple regression model. Our results indicate that temporal stability in
the beta band is correlated with rigidity–bradykinesia. It is suggested that loss of beta reactivity is deleterious
to basal ganglia function over and above any concomitant change in absolute level of beta synchrony. The CV
of LFP beta band amplitude may potentially provide an additional index of clinical state suitable for feedback
control in closed loop stimulation therapy.
© 2012 Elsevier Inc. Open access under CC BY license.Introduction
There is an increase in correlative evidence suggesting that exag-
gerated oscillatory synchronisation in the beta frequency band may
be related to motor impairment in patients with Parkinson's Disease
(Jenkinson and Brown, 2011). Such synchronisation is usually indi-
rectly measured as the average spectral amplitude or power of beta
frequency band activity in the LFP recorded in basal ganglia sites tar-
geted during functional neurosurgery. LFP ﬂuctuations largely reﬂect
the temporal and spatial summation of presynaptic neuronal activity
(Goldberg et al., 2004; Magill et al., 2004; Mitzdorf, 1985) and there-
fore LFP amplitude or power indexes the strength of synchronisation,
the density and (up to an electrode dependent limit) the spatial extent
of the involved neural pool. However, a further variable is oftenDeep brain stimulation; KS,
, Lempel–Ziv complexity; STN,
rating scale.
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license.overlooked, and this is the constancy of these features over time. Syn-
chronisation and the size of the affected neural pool can change from
moment to moment, leading to ﬂuctuations in spectral amplitude or
power over time that affect the average signal. Consider, for example,
two networks. One is almost completely synchronous or very exten-
sive for a brief instant, and then barely synchronous or very small for
the rest of the time. Another network is modestly synchronised and
extensive throughout. The two networks may lead to similar time av-
eraged LFP power but the impact upon normal functioningmay poten-
tially be very different. We have previously reported that the spatial
extent of beta band phase synchronisation in the region of the STN
correlates with rigidity — bradykinesia (Pogosyan et al., 2010). We
now test whether the temporal stability of synchronisation as inferred
from LFP amplitude also correlates with rigidity — bradykinesia.
A correlation between the temporal stability of beta band ampli-
tude and motor impairment would be important for several reasons.
First, ﬂuctuations in amplitude might imply the existence of processes
that can disrupt pathological synchrony, which might provide clues
for new therapeutic approaches, as in epilepsy (Loddenkemper et al.,
2001). Secondly, the temporal stability of beta band amplitude might
provide a faithful indicator of current motor state suitable as a feed-
back signal in the closed loop control of therapeutic deep brain
384 S. Little et al. / Experimental Neurology 236 (2012) 383–388stimulation (Rosin et al., 2011). Temporal stability might provide a
faithful feedback signal in its own right, or, if proven to carry non-
redundant information, through combination with other measures.
We elected to assess the temporal stability of the amplitude of the
LFP in the beta range with a simple measure, the standard deviation
of the time varying beta band amplitude normalised by the mean
beta band amplitude, otherwise known as the coefﬁcient of variation
(CV). There is some hope that the CV of LFP amplitudemight correlate
with clinical state, given the correlation of a complexity measure of
beta activity with motor impairment (Chen et al., 2010). However,
the CV and complexity, as estimated using the Lempel–Ziv complexi-
ty are not equivalent. The Lempel–Ziv complexity captures not only
linear dependencies in the structure of the LFP over time but also
nonlinear interactions between frequencies (Chen et al., 2010) mak-
ing it a more difﬁcult statistic to estimate and a less intuitive one.
We also elected to assess the strength of correlations between
motor impairment and CV in the lower and upper beta frequency
band, and to investigate this both with respect to the off medication
state and change with medication, — aspects not explored with the
Lempel–Ziv complexity. Consideration of the lower and upper beta
frequency bands was motivated by studies which suggest a differen-
tial functional and pathological signiﬁcance between these frequency
ranges (López-Azcárate et al., 2010; Marceglia et al., 2006, 2007;
Priori et al., 2004).
Methods
Patients and surgery
We investigated the relationship between time related ﬂuctua-
tions in the amplitude of the beta band signal and motor impairment,
as indexed by the motor UPDRS, in the off medication state at rest and
in response to levodopa treatment in two independent archival data-
sets; an intraoperative off medication rest dataset and a post-
operative dataset which included data from on and off medication.
The surgical target was the STN and the DBS electrode used was
model 3389 (Medtronic Neurological Division, Minneapolis, USA).
Rest off medication dataset
Eighteen patients with advanced idiopathic PD were recorded
intra-operatively in the off medication state (mean age 60.4±
(SEM) 7.0 yrs, disease duration 15.2±5.4 yrs, mean pre-operative
UPDRS motor score 42.9±15.7 off drugs and 11.1±7.4 after levodo-
pa challenge). These patients have been reported previously
(Pogosyan et al., 2010); however, the earlier study only investigated
the correlation between LFP phase coherence and clinical features.
LFPs were recorded from bipolar pairs of adjacent electrode contacts
to maximise spatial selectivity. This afforded a series of three bipoles,
01, 12 and 23, from the four electrode contacts of each electrode,
where contact pair 01 was the most caudal. Intra-operative record-
ings involved a staged descent in 2 mm steps from above the STN
with periods of recording at each level. All patients showed a step in-
crease in beta power between contacts 01 on entering the STN of at
least 100%. This depth has been termed the physiologically deﬁned
target level (Yoshida et al., 2010). Full details of the patients, surgery,
recordings and physiological targeting are included in the previous
report (Pogosyan et al., 2010). Data from this cohort were ampliﬁed,
pass band ﬁltered between 1 and 80 Hz and sampled at 184 Hz (Bio-
potential Analyzer Diana, St Petersburg, Russia). Thereafter LFPs were
examined off-line in Spike2 software (Cambridge Electronics Design,
Cambridge, UK).
On–Off medication dataset
Ten patients (20 sides) were recorded in the off state and follow-
ing levodopa challenge in the post-operative period prior to battery
and stimulator implantation (age 60.6±2.5 yrs, disease duration11.9±1.4 yrs, pre-operative UPDRS motor score 45.1±2.5 off drugs
and 22.4±4.1 after levodopa challenge). Full details of patients, sur-
gery and recording have previously been reported separately for
nine of the subjects (Kühn et al., 2006a) and one subject (case 5
in (Kühn et al., 2006b)). LFPs were recorded from bipolar pairs of
adjacent electrode contacts as above. Data from this cohort were
ampliﬁed and ﬁltered at 1–250 Hz using a custom-made, high im-
pedance ampliﬁer (which had as its front end input stage the
INA128 instrumentation ampliﬁer, Texas Instruments Incorporated
12500 TI Boulevard Dallas Texas, USA) and recorded through a
1401 A-D converter (Cambridge Electronic Design) onto a computer
using Spike2 software (Cambridge Electronic Design). Signals were
sampled at ≥625 Hz.
Spectral analysis
Spectral decomposition with a continuous wavelet transform was
performed for both datasets using a Morlet wavelet, due to its efﬁ-
cient time frequency resolution and lack of assumptions regarding
stationarity (Muthuswamy and Thakor, 1998; Pogosyan et al.,
2010). Convolution of each LFP time series for each subject was car-
ried out with an array of appropriately scaled wavelets to generate
a complex time series for each frequency band between 1 and 80 Hz
for the duration of each recording, the modulus of which denoted
the instantaneous amplitudes for each frequency at all points during
the recording. The wavelet transformation is in a sense therefore a
band-pass ﬁltering of the LFP such that the resulting time series
shows the magnitude of oscillations over the time of the recording
in the speciﬁc ﬁltered frequency (Fig. 1). As can be seen, there was
variation in the amplitudes at the speciﬁc frequencies that then
were used to calculate the coefﬁcient of variation (CV) by dividing
the standard deviation of each frequency speciﬁc amplitude time se-
ries by the corresponding mean amplitude. This afforded a single
value of CV for each frequency for the duration of the whole record.
As such, for each subject a single value of amplitude variability (CV)
was obtained for each frequency resulting in 80 frequency speciﬁc
CVs (1–80 Hz) per subject for further correlation.
The CV is therefore scale invariant and relatively immune from
confounds introduced at the between subject level such as differences
in stun effects or small variation in targeting between sides and sub-
jects. Recording lengths were 65±2.4 s (SEM) for the intraoperative
dataset and 286±15 s (SEM) for the levodopa response dataset. Pro-
cessing was performed in MATLAB (v. 7.11.0, R2010b, The Math-
works, Natik, MA, USA) with custom written scripts.
Correlations
The CV averaged across the frequencies within the low beta (beta
1=12–20 Hz) and high beta (beta 2=21–33 Hz) frequency bands
for each side was correlated with clinical scores derived from the
motor UPDRS across subjects. The clinical scores were total hemibody
score (sum of unilateral UPDRS motor score sub-items 20–26),
rigidity-bradykinesia hemibody score (sum of unilateral UPDRS
motor score sub-items 22–26) and rest tremor hemibody score
(sum of unilateral UPDRS motor score sub-items 20 and 21 for arm
and leg) contralateral to the recording site. The percentage change
of UPDRS for each item was calculated as ([hemibody scoreON−
hemibody scoreOFF]/hemibody scoreOFF)×100. Similarly, percentage
changes in the CV was calculated as [CVON−CVOFF]/CVOFF and in
the signal amplitude as [AmplitudeON−AmplitudeOFF]/AmplitudeOFF.
Kolmogorov–Smirnov testing revealed that the intra-operative
rest data were not normally distributed and therefore correlations
were performed using Spearman's correlation coefﬁcient (rho) and
data normalised using a Boxcox power transformation (lamda=0.3)
prior to multiple linear regression. The treatment change dataset
ﬁtted a normal distribution (KS p>0.05) and therefore was not trans-
formed prior to multiple regression. Statistical analyses were per-
formed using SPSS version 19 (SPSS Inc., Chicago, IL, USA).
Fig. 1. Schematic showing amplitude variability in beta in one subject and corresponding instantaneous amplitude time series. [A] Filtered beta LFP signal from subject 12 (intrao-
perative rest data) demonstrating marked ﬂuctuations in beta amplitude over time and a low hemibody UPDRS score=23. [B] Instantaneous amplitude time series with mean am-
plitude (thick dashed line) and standard deviation also illustrated (thin dashed lines). Instantaneous amplitude is calculated by convolution of the LFP with an appropriately scaled/
frequency speciﬁc wavelet to determine the amplitude of the selected frequency band at all points in time. The standard deviation of the instantaneous amplitude time series cap-
tures the variability of amplitude over time for that frequency. This is then normalised by the mean amplitude in that frequency band to derive a scale invariant measure of am-
plitude variability — the coefﬁcient of variation of amplitude over time (CV), for each record.
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Intra-operative rest recordings off medication (18 subjects, 36 sides)
Spectral analysis of the LFP recorded at the physiologically deﬁned
target level revealed that all 18 subjects had at least one spectral peak
within the beta band (13–35 Hz). The power spectrum averaged
across all records demonstrated two deﬁned peaks at 16 Hz and
25 Hz, within the low beta (beta 1) and high beta (beta 2) frequency
bands, respectively (Fig. 2A).
The CV of intra-operatively recorded amplitude was calculated
with 1 Hz resolution over 1 to 80 Hz and correlated against the pre-
surgical motor UPDRS score. The correlation between the CV of the
amplitude envelope and UPDRS scores was signiﬁcant and broad, al-
beit restricted to the beta 2 range (Figs. 2B,C). This relationship was
strongest at the frequency of the peak (25 Hz) in the beta 2 range of
the group mean power spectrum (rho=−0.75, pb0.001; Fig. 3). Cor-
relations were negative so that a higher CV was associated with more
modest motor impairment in the contralateral limbs.
Having conﬁrmed a correlation between hemibody motor UPDRS
scores and the temporal variability of oscillatory activities in the
beta frequency band, we separately calculated the mean CV across
the frequencies within the beta 1 and beta 2 ranges and correlated
these against total hemibody motor UPDRS scores. The Spearman's
correlation coefﬁcient (rho) of mean beta 1 CV vs UPDRS was
−0.44 (p=0.008) and −0.59 for mean beta 2 CV (pb0.001). This
procedure was repeated for alpha (7–11 Hz) which demonstrated a
weaker correlation with borderline signiﬁcance (rho=−0.34,
p=0.044) and for gamma (40–80 Hz), which revealed no correlation
(rho=−0.08, p=0.65).
The relationship between beta CV and clinical features was not only
frequency but also impairment selective. Correlations between beta 1
and beta 2 CV and contralateral rigidity–bradykinesia hemibody scoresalone were signiﬁcant (rho=−0.45, p=0.006 and rho=−0.53,
pb0.001), but there was no relationship between beta 1 and beta 2
CV and contralateral tremor hemibody scores (rho=−0.26, p=0.11
and rho=−0.24, p=0.16). Correlations were also found to be highly
focal. The primary analysis was conducted using STN recordings made
at the physiologically deﬁned target level (Yoshida et al., 2010). We
therefore repeated the analysis using data recorded from 2 mm above
the physiological target level and correlations were absent for both
beta 1 and beta 2 (rho=−0.22, p=0.2 and rho=−0.18, p=0.3).
CV is relatively scale independent, as it is normalised by mean am-
plitude. To be sure that we were not confounding our predictions of
the variance in clinical state with a dependency of the latter on ampli-
tude, we further performed multiple regression analysis using CV and
amplitude in the two beta sub-bands. The overall model accounted
for 41% of the variance in contralateral hemibody UPDRS scores
(r2=0.41; F(4,31)=7.060, pb0.001) and 29% of contralateral rigidi-
ty–bradykinesia hemibody UPDRS scores (r2=0.29; F(4,31)=4.622,
p=0.005). However, only the CV in the beta 2 band strongly correlated
with contralateral hemibody UPDRS scores and was a signiﬁcant
predictor of clinical impairment (standardised b coefﬁcient −0.54,
p=0.009), when accounting for the remaining variables in the regres-
sion model.
On/Off dataset (10 subjects, 17 sides)
We next investigated whether treatment with levodopa increased
the CV and did so in proportion to treatment induced improvement in
rigidity–bradykinesia. To this end we analysed a second archival data-
set that recorded STN LFPs in patients both off and on levodopa, con-
currently with clinical assessments. Two recordings were found to
not show a distinct peak within the beta range and were therefore ex-
cluded from further analysis. The CV estimated for a further recording
was identiﬁed as a signiﬁcant outlier and was excluded following
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Fig. 3. Scatter plot of CV and contralateral hemibody motor UPDRS off medication.
Shown for the frequency (25 Hz) of the peak of activity in the Beta 2 range in the
group mean spectrum (Fig. 2A). There is a negative correlation between CV and
UPDRS off medication (rho=−0.75, pb0.001).
Fig. 2. Spectral correlations. [A] Mean STN LFP amplitude spectral density across all
subjects, shown as % of total in each 1 Hz frequency band. There are peaks at 16 and
25 Hz, in the beta 1 and beta 2 ranges, respectively. [B] and [C] show Spearman's cor-
relation coefﬁcient (rho) and its signiﬁcance between the CV of STN LFP amplitude at
a given frequency and contralateral hemibody (HB) motor UPDRS scores. There is a
strong and broad correlation between the STN LFP CV at a given frequency and contra-
lateral hemibody motor UPDRS scores in the beta 2 range.
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in the remaining 17 sides, with factor medication and beta frequency
range (beta 1 or beta 2), revealed an effect of levodopa (F(1,16)=
6.57, p=0.021) and a trend towards interaction between medication
and beta range (F(1,16)=3.29, p=0.089) but no main effect of beta
frequency range. Post-hoc t-tests showed that there was a signiﬁcant
reduction in beta 1 amplitude (38%; p=0.03) and a smaller but sig-
niﬁcant reduction in beta 2 amplitude (21%; p=0.042). An ANOVA
of CV with the same factors revealed no main effects or interactions.
Despite the above, we found a signiﬁcant negative correlation be-
tween the levodopa-induced change in mean beta 2 CV and the
change in contralateral rigidity–bradykinesia scores (rho=−0.66,
p=0.004; Fig. 4). Greater increases in CV upon treatment were asso-
ciated with greater improvements in rigidity–bradykinesia upon
treatment. This was again found to be symptom selective as there
was no relationship between beta 2 CV and contralateral tremor
hemibody scores (rho=0.14, p=0.6). There was also no signiﬁcant
association between change in beta 1 CV and change in clinical
state. Note too that the change in CV cannot alone account for im-
provement in clinical state with medication, as a minority of patients
showedmodest improvement despite drops in CV after treatment. On
two sides, each from different patients, the drop in CV after treatment
related to the complete suppression of the beta 2 peak that was for-
merly present in the off medication state.
Levodopa-induced changes in beta band amplitude are known to
correlate with improvements in motor signs. We therefore reprised
our previous multiple regression analysis, but using levodopa-
induced changes in amplitude, CV and clinical state. The overall
model accounted for 44% of the variance in contralateral hemibody
rigidity-bradykinesia scores (r2=0.44, F(4,12)=4.20 p=0.024).
However, only the change in CV in the beta 2 band was correlated
with the change in contralateral hemibody UPDRS (Standardised b
coefﬁcient −1.08, p=0.019), when accounting for the remaining
variables in the regression model.Discussion
This study demonstrates that the normalised variability (CV) of
the beta frequency band component of the STN LFP over time strongly
predicts the variance between patients in rigidity–bradykinesia. Spe-
ciﬁcally, the greater the CV at rest and the greater the increase in CV
following levodopa treatment, the lower the bradykinesia–rigidity-60 -40 -20 0
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Fig. 4. Scatter plot of change in mean beta 2 CV and change in contralateral hemibody
rigidity-bradykinesia score in response to levodopa. The patients with the best im-
provement (more negative % change) in rigidity-bradykinesia have the greater in-
crease in beta 2 CV.
387S. Little et al. / Experimental Neurology 236 (2012) 383–388score at rest and the greater the improvement in rigidity–bradykine-
sia with treatment. These effects were found to be frequency and im-
pairment speciﬁc, as well as focal.
There are several reports that treatment induced suppressions of
beta amplitude or power in the STN LFP correlate with treatment in-
duced clinical improvement (Kühn et al., 2006a; Kühn et al., 2009;
Ray et al., 2008). However, it has been less clear whether beta ampli-
tude or power in the off medication state correlates with motor im-
pairment. Several studies found no such correlation (Kühn et al.,
2006a; Kühn et al., 2009; Ray et al., 2008; Weinberger et al., 2006).
In contrast, two studies have reported signiﬁcant, correlations be-
tween beta band power and rigidity-bradykinesia in the off-
medication state (rho=0.428 in (López-Azcárate et al., 2010) and
rho=0.329 in (Özkurt et al., 2011)). Two other studies have reported
correlations under similar circumstances using the LZC measure in
the beta band (Chen et al., 2010) or LFP phase synchronisation across
electrode contacts (Pogosyan et al., 2010). Our study reinforces these
ﬁndings by demonstrating that the CV of beta 2 band LFP activity, in
particular, correlates off medication with rigidity–bradykinesia
(rho=−0.59), and extends them by showing that, like treatment in-
duced changes in beta band amplitude or power, treatment induced
changes in CV also correlate with treatment induced changes in bra-
dykinesia and rigidity (rho=−0.66).
Thus another feature of synchronisation, its temporal variability,
may impact on clinical state. Time averaged LFP power/amplitude es-
timates index the strength of synchronisation, the density and spatial
extent of the involved neural pool and the constancy of these features
over time. However, power/amplitude estimates cannot infer the rel-
ative contributions of these different features and their relative path-
ophysiological importance remains unclear. Thus, measures reﬂecting
individual features, like the spatial extent of phase synchrony in the
beta band (Pogosyan et al., 2010) and the CV of beta band activity
may potentially provide complementary, rather than redundant, in-
formation about clinical state. This raises the possibility that mea-
sures can be combined to strengthen clinical correlations. Özkurt et
al. (2011) showed this with beta power and the high frequency oscil-
lation power ratio, and here we demonstrate that combining beta
amplitude and beta CV in a multiple regression model accounts
for 41% of the variance in contralateral hemibody UPDRS scores off
medication. Similarly, combining levodopa-induced change in beta
amplitude and beta CV in a multiple regression model accounts
for 44% of the variance in change in contralateral hemibody rigidity–
bradykinesia scores. This multivariate approach may prove useful in
selecting feedback signals that faithfully reﬂect current motor state
and are therefore suitable for closed-loop control of DBS (Rosin et al.,
2011). This may be particularly the case with beta amplitude and its
CV, as both are computationally simple to calculate, potentially limiting
drains on battery power, and correlate over a large spectrum of clinical
state as suggested by the correlations evident with rest and treatment
induced changes. Nevertheless, it is important to stress that although
beta amplitude and CVhave been shown to explain a signiﬁcant portion
of the variance in rigidity-bradykinesia across patients, this has yet to be
demonstrated within subjects, a necessary pre-requisite for any signal
or signal combination to be used in closed loop control.
It should be noted that the OFF drug motor UPDRS scores con-
trasted with the ﬁrst intra-operatively recoded LFP data set were
assessed a median of 2 months prior to surgery (range 1 day–
6 months). This is likely to have, if anything, led to an under-
estimation of clinical correlations with CV. Still, other studies demon-
strating a correlation between drug-induced change in beta band LFP
activity and change in bradykinesia–rigidity have been based on
motor examinations that were performed up to a few months before
surgery and have shown no difference in the residuals from the corre-
lations between patients examined in this way and those assessed on
the same day as electrophysiological recordings (Kühn et al., 2009;
Ray et al., 2008). This may be because the changes in UPDRS motorscores over comparable time intervals can be small and insigniﬁcant
(Olanow et al., 2004).
An interesting aspect of the current study that has thus far
not been discussed is the relative focussing of correlations with
bradykinesia–rigidity in the beta 2 rather than beta 1 frequency band.
This is in accord with the differential reactivities in these two bands
under different experimental conditions, including a more pronounced
response to treatment with levodopa in the beta 1 than beta 2 range
(López-Azcárate et al., 2010; Marceglia et al., 2006, 2007; Priori et al.,
2004). Of the two bands, STN activity in the beta 2 band is most syn-
chronised with cortical activity (Hirschmann et al., 2011; Litvak et al.,
2011) and may therefore have the greater facility to directly disrupt
motor function. However, it has also been suggested that it is not so
much the precise frequency of synchronisation in the beta band that
may be important, but rather how strong synchronisation is (Kühn
et al., 2009). For the moment, the relative contributions of beta 1 and
beta 2 frequency bands, if any, to motor impairment remain to be
clariﬁed.
Where does the temporal variability of beta activity arise? Could it
be an emergent property of stochastic noise in the underlying neural
networks, or secondary to deterministic processes? Modelling studies
have suggested that beta oscillations in basal ganglia networks are at
the boundary of synchronous and non-synchronous regimes in
Parkinson's disease, and that small ﬂuctuations in intermittent syn-
chrony can be generated just by moderately increased coupling
strength in the basal ganglia circuits due to the lack of dopamine
(Park et al., 2011). Dopaminergic therapy suppresses tonic levels of
beta (Hammond et al., 2007) and it has recently been suggested that
the phasic release of endogenous dopamine in response to salient
cues in the internal and external environment causes moment-to-
moment ﬂuctuations in beta activity in the basal ganglia (Jenkinson
and Brown, 2011). Smaller CVs might then reﬂect greater attenuation
of reactive dopamine release secondary to greater dopaminergic
denervation.
Correlation does not necessarily imply causation and whether the
behaviour of neuronal populations in the beta band is causally linked
to bradykinesia and rigidity or the relationship between the electro-
physiological and clinical state is epiphenonal remains to be established
(Jenkinson and Brown, 2011; Timmermann and Florin, 2012;
Weinberger et al., 2009). Assuming that temporal variability in the de-
gree of synchronisation is causally important, how might this come
about? Our data would suggest that it is not simply secondary to in-
creasing levels of background beta synchrony, as the correlation be-
tween temporal variability and motor state persisted when we
normalised variability by amplitude, and remained signiﬁcant in a mul-
tiple regression model that included amplitude. The implication is that
there may be something disadvantageous to basal ganglia function
about loss of spontaneous beta reactivity that is relatively independent
of the absolute level of beta synchrony. One possibility is that predictive
preparation for voluntary action is diminished without phasic modula-
tion of dopamine and beta (Jenkinson and Brown, 2011).
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